SCHEMBL10102706

SCHEMBL10102706

CCOC(=O)Cc1cc2cc(C)ccc2nc1-c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.52
ALDH1A1 P00352 5/20 0.52
L3MBTL1 Q9Y468 4/20 0.52
MAPT P10636 3/20 0.52
TDP1 Q9NUW8 2/20 0.52
HPGD P15428 1/20 0.52
POLB P06746 1/20 0.50
MAPK1 P28482 1/20 0.48
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
ATM Q13315 1/20 0.47
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
PKM P14618 1/20 0.46
NFKB1 P19838 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
KLK7 P49862 1/20 0.46
LMNA P02545 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3384876 0.86 KDM4E (0.53) KDM4EALDH1A1L3MBTL1MAPTTDP1
SCHEMBL1884067 0.79 KDM4E (0.57) KDM4EALDH1A1L3MBTL1MAPTTDP1
SCHEMBL3386971 0.77 KDM4E (0.54) KDM4EALDH1A1L3MBTL1MAPTTDP1
SCHEMBL1891795 0.76 KDM4E (0.57) KDM4EALDH1A1L3MBTL1MAPTTDP1
SCHEMBL12749462 0.75 KDM4E (0.55) KDM4EALDH1A1L3MBTL1MAPTTDP1
SCHEMBL10102546 0.74 KDM4E (0.41) KDM4EALDH1A1L3MBTL1TDP1HPGD
SCHEMBL5381820 0.74 LMNA (0.54) KDM4EALDH1A1L3MBTL1MAPTTDP1
SCHEMBL21799191 0.73 KDM4E (0.54) KDM4EALDH1A1L3MBTL1MAPTTDP1
SCHEMBL9863054 0.72 PKM (0.54) KDM4EALDH1A1L3MBTL1MAPTTDP1
SCHEMBL28529940 0.72 PDE10A (0.73) KDM4EALDH1A1L3MBTL1MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207345-B2 Antitumor agents; use in combination with other drugs such as pentamidine MERCK PATENT GMBH (DE) 2012-06-26 US disclosed
US-8207345-B2 Antitumor agents; use in combination with other drugs such as pentamidine MERCK PATENT GMBH (DE) 2012-06-26 US disclosed
US-20080200451-A1 Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 MERCK PATENT GMBH (DE) 2008-08-21 US disclosed
US-20080200451-A1 Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 MERCK PATENT GMBH (DE) 2008-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200451-A1 Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 KIF5A, KIF5C, KIF5B KDM4E 2071/4885ALDH1A1 3886/4885L3MBTL1 893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.